Feb 06, 2014 7:00am EST Can-Fite Submitted Phase II Study Protocol with CF102 to Treat Patients with Advanced Liver Cancer
Jan 13, 2014 7:00am EST Can-Fite to Present New Clinical Data from Further Analysis of its Clinical Studies of CF101 for the Treatment of Rheumatoid Arthritis and Psoriasis at OneMedForum and Biotech Showcase held in San Francisco, California
Dec 31, 2013 7:00am EST OphthaliX to Retrospectively Analyze Phase III Dry Eye Syndrome Study Data Based on A3 Adenosine Receptor Biomarker
Dec 30, 2013 1:00am EST OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
Dec 23, 2013 7:00am EST Can-Fite BioPharma Announces Top-Line Results of Phase IIb Study with CF101 as a Monotherapy for Rheumatoid Arthritis
Dec 19, 2013 7:00am EST Can-Fite Granted U.S. Patent for Utilization of A3 Adenosine Receptor as Biomarker to Predict Patient Response to CF101 in Autoimmune Inflammatory Indications
